"A new study of the longest-acting form of injectable PrEP, lenacapavir, has shown no adverse interactions with hormone therapy for trans women and men. Marketed under the brand name Yeztugo by Gilead Sciences, the twice-annual PrEP injectable was approved by the FDA in June, marking a big advance in long-lasting protection against HIV, the virus that causes AIDS. GlaxoSmithKline's PrEP injectable cabotegravir, known as Apretude and approved for use in 2021, provides two months of protection."
"While trans people make up about 1% of the U.S. population, they accounted for 2% of new HIV diagnoses in 2019, according to the Centers for Disease Control and Prevention. Compounding that statistic, prior studies indicate some trans people at high risk for HIV transmission are hesitant to take antiretrovirals for HIV prevention over concerns about their impact on hormone therapy."
A study found no clinically significant impact of twice-annual lenacapavir injections on feminizing or masculinizing hormone concentrations for trans women and men. Lenacapavir, marketed as Yeztugo, received FDA approval and offers long-lasting HIV pre-exposure prophylaxis compared with two-month protection from cabotegravir (Apretude). Hormone levels remained generally comparable before and after lenacapavir administration. Trans people face disproportionate HIV diagnoses and express hesitancy to use antiretrovirals because of concerns about hormone interactions. Low PrEP uptake and adherence among gender-diverse populations could improve with longer-acting injectable alternatives.
Read at LGBTQ Nation
Unable to calculate read time
Collection
[
|
...
]